Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Link opens in a new tab
Search content at Penn State
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
CLINICAL TRIAL: PI TRIAL OF IMMUNOSTIMULATION JVRS-100 FOR RELAPSED OR REFRACTOR
Leuenberger, Urs U.A
(PI)
Claxton, David
(PI)
Department of Medicine
Division of Hematology and Oncology
Penn State Cancer Institute
Cancer Institute, Experimental Therapeutics
Project
:
Research project
Overview
Fingerprint
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Clinical Trials
100%
Cationic Lipids
100%
Recommended Phase 2 Dose
100%
Lipid-DNA
100%
Dose Level
100%
Interferon-α (IFN-α)
100%
Immunostimulation
100%
Refractor
100%
Adaptive Immunity
50%
Innate Immunity
50%
Maximum Tolerated Dose
50%
2-stage
50%
Titration
50%
Plasmid DNA (pDNA)
50%
NK Cell Activity
50%
Crisps
50%
Tolerability
50%
DNA Complex
50%
NKT Cells
50%
Fibonacci
50%
Non-coding DNA
50%
Dose-limiting Toxicity
50%
Phase I Trial
50%
Interleukin-12 (IL-12)
50%
Dismal Prognosis
50%
T Cell Activation
50%
B Cell Activation
50%
Pharmacology, Toxicology and Pharmaceutical Science
Interferon
100%
Clinical Trial
100%
Lipid
100%
Tolerability
50%
Phase I Trials
50%
Plasmid DNA
50%
Leukemia
50%
Cytokine
50%